Log in with your email address username.


Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

[Comment] Prolonged antiplatelet therapy after drug-eluting stents

After use of intracoronary drug-eluting stents, a regimen of two antiplatelet agents (ie, dual antiplatelet therapy [DAPT]) is necessary to prevent stent thrombosis, a complication associated with myocardial infarction and death. Conventional DAPT includes aspirin and a P2Y12 platelet receptor inhibitor such as clopidogrel, prasugrel, or ticagrelor.1 The optimum duration of DAPT is the subject of much debate; prevention of stent thrombosis has to be balanced against the elevated risk of bleeding associated with two agents.